Novartis CEO Vas Narasimhan's R&D update spotlights next wave of drug stars as well as late-stage favorites
As one of the biggest spenders in biopharma R&D, Novartis execs love to tout the scope of its late-stage pipeline, spotlighting the winners most likely to create blockbuster revenue streams in the near future.
Building on the 5 drug approvals the pharma giant expects to end the year with, Novartis CEO Vas Narasimhan — who’s done a slate of acquisitions topped by the recent $9.7 billion MedCo buyout — tapped the top emerging drugs as:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.